ACE2 and COVID-19: To unequivocally establish that some COVID-19 patients develop anti-SARS-CoV-2 immune responses that include abzymes, it would be necessary to isolate discrete monoclonal antibodies from patients with ACE2 substrate cleavage activity and then characterize those monoclonal antibodies in detail.